Yao Jie An Kang-B (02617) published the exploratory clinical results of its core product, Tenoxtatene, for the treatment of bile duct cancer.

Zhtng Cijng APP News, China Medical-B(02617) announced recently that the exploratory phase 2 clinical trial results of the company's core product, Erlotinib, for bile duct cancer in the United States were published in "The Lancet, Gastroenterology and Hepatology" (impact factor 38.6).